Redesigning kinase inhibitors to enhance specificity

Journal of Medicinal Chemistry

Volumn 51, Issue 16, 2008, Pages 4890-4898

  Crespo, Alejandro ^a   Zhang, Xi ^b   Fernández, Ariel ^a  

^a Rice University   (United States)

^b RICE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE 2; DASATINIB; DEATH ASSOCIATED PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FOCAL ADHESION KINASE 1; GEFITINIB; GLYCOGEN SYNTHASE KINASE 3BETA; IMATINIB; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; JANUS KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE; P21 ACTIVATED KINASE 1; PELITINIB; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOTRANSFERASE INHIBITOR; PIM 2 KINASE; PROTEIN KINASE FYN; PROTEIN KINASE LCK; PROTEIN KINASE PIM 1; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SORAFENIB; STAUROSPORINE; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DRUG BINDING; DRUG SAFETY; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HYDROGEN BOND;

AMINOQUINOLINES; ANILINE COMPOUNDS; DRUG DESIGN; ENZYME INHIBITORS; HYDROGEN BONDING; MODELS, MOLECULAR; PHOSPHOTRANSFERASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAUROSPORINE; SUBSTRATE SPECIFICITY;

EID: 50249148317     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800453a     Document Type: Article

References (47)

1. Gibbs, J.; Oliff, A. Pharmaceutical research in molecular oncology. Cell 1994, 79, 193-198.
2. Levitski, A.; Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science 1995, 267, 1782-1788.
3. Donato, N. J.; Talpaz, M. Clinical use of tyrosine kinase inhibitors: therapy for chronic myelogenous leukemia and other cancers. Clin. Cancer Res. 2000, 6, 2965-2966.
4. Dancey, J.; Sausville, E. A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discovery 2003, 2, 296-313.
5. Tibes, R.; Trent, J.; Kurzrock, R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 357-384.
6. Chen, J.; Zhang, X.; Fernández, A. Molecular basis for specificity in the druggable kinome: sequence-based analysis. Bioinformatics 2007, 23, 563-572.
7. Knight, Z. A.; Shokat, K. M. Features of selective kinase inhibitors. Chem. Biol. 2005, 12, 621-637.
8. Fabian, M. A.; Biggs, W. A.; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgand, S.; Insko, D. E.; Insko, M. A.; Lai, A.; Lélias, J. M.; Mehta, S.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zirrankar, P. P.; Lockhart, D. A. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23, 329-336.
9. Karaman, M. K.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26, 127-132.
10. Druker, B. J. Molecularly targeted therapy: have floodgates opened. Oncologist 2004, 9, 357-360.
11. Kerkelä, R.; Grazette, L.; Yacobi, R.; Iliescu, C.; Patten, R.; Beahm, C.; Walters, B.; Shevtsov, S.; Pesant, S.; Clubb, F. J.; Rosenzweig, A.; Salomon, R. N.; Van Etten, R. A.; Alroy, J.; Durand, J.; Force, T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 2006, 12, 908-916.
12. Force, T.; Krause, D. S.; Van Etten, R. A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 2007, 7, 332-344.
13. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discovery 2002, 1, 493-502.
14. Atkins, M.; Jones, C. A.; Kirkpatrick, P. Sunitinib maleate. Nat. Rev. Drug Discovery 2006, 5, 279-280.
15. Rini, B. I. Sorafenib. Expert Opin. Pharmacother. 2006, 7, 453-461.
16. McIntyre, J. A.; Er, J.; Bayes, M. Dasatinib. Treatment of leukemia treatment of solid tumors Bcr-Abl and Src kinase inhibitor. Drugs Future 2006, 31, 291-303.
17. Leighl, N. B.; Res, D. Erlotinib: Profile report. Drugs Ther. Perspect. 2006, 22, 1-2.
18. Cappuzzo, F.; Finocchiaro, G.; Metro, G.; Bartolini, S.; Magrini, E.; Cancellieri, A.; Trisolini, R.; Castaldini, L.; Tallini, G.; Crino, L. Clinical experience with gefitinib: An update. CRC Crit. Rev. Oncol. Hematol. 2006, 58, 31-45.
19. Fernández, A.; Sanguino, A.; Peng, Z.; Ozturk, E.; Chen, J.; Crespo, A.; Wulf, S.; Shavrin, A.; Qin, C.; Ma, J.; Trent, J.; Lin, Y.; Han, H.; Mangala, L. S.; Bankson, J. A.; Gelovani, J.; Samarel, A.; Bornmann, W.; Sood, A. K.; López-Berestein, G. An anticancer C-kit kinase inhibitor is re-engineered to make it more active and less cardiotoxic. J. Clin. Invest. 2007, 117, 4044-4054.
20. Demetri, G. Structural reengineering of imatinib to decrease cardiac risk in cancer therapy. J. Clin. Invest. 2007, 117, 3650-3653.
21. Crunkhorn, S. Anticancer drugs: Redesigning kinase inhibitors. Nat. Rev. Drug Discovery 2008, 7, 120-121.
22. Crespo, A.; Fernández, A. Kinase packing defects as drug targets. Drug Discovery Today 2007, 12, 917-923.
23. Fernández, A.; Scheraga, H. A. Insufficiently dehydrated hydrogen bonds as determinants of protein interactions. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 113-118.
24. Fernández, A.; Scott, L. R. Adherence of packing defects in soluble proteins. Phys. Rev. Lett. 2003, 91, 018102.
25. Fernández, A.; Scott, L. R. Dehydron: A structurally encoded signal for protein interaction. Biophys. J. 2003, 85, 1914-1928.
26. Fernández, A. Keeping dry and crossing membranes. Nat. Biotechnol. 2004, 22, 1081-1084.
27. Pietrosemoli, N.; Crespo, A.; Fernández, A. Dehydration propensity of order-disorder intermediate regions in soluble proteins. J. Proteome Res. 2007, 6, 3519-3526.
28. Fernández, A. Incomplete protein packing as a selectivity filter in drug design. Structure 2005, 13, 1829-1836.
29. Fernández, A.; Sanguino, A.; Peng, Z.; Crespo, A.; Ozturk, E.; Zhang, X.; Wang, S.; Bornmann, W.; López-Berestein, G. Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target. Cancer Res. 2007, 67, 4028-4033.
30. Fernández, A.; Berry, R. S. Molecular dimension explored in evolution to promote proteomic complexity. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 13460-13465.
31. Link, J. T.; Raghavan, S.; Danishefsky, S. J. First total synthesis of staurosporine and ent-staurosporine. J. Am. Chem. Soc. 1995, 117, 552-553.
32. Wissner, A.; Overbeek, E.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Mamuya, N.; Rosfjord, E. C.; Discafani, C.; Davis, R.; Shi, X.; Rabindran, S. K.; Gruber, B. C.; Ye, F.; Hallett, W. A.; Nilakantan, R.; Shen, R.; Wang, Y.; Greenberger, L. M.; Tsou, H. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem. 2003, 46, 49-63.
33. Fernández, A.; Maddipati, S. The a priori inference of cross reactivity for drug-targeted kinases. J. Med. Chem. 2006, 49, 3092-3100.
34. Zhao, B.; Bower, M. J.; McDevitt, P. J.; Zhao, H.; Davis, S. T.; Johanson, K. O.; Green, S. M.; Concha, N. O.; Zhoud, B. S. Structural basis for Chk1 inhibition by UCN-01. J. Biol. Chem. 2002, 277, 46609-46615.
35. Atwell, S.; Adams, J. M.; Badger, J.; Buchanan, M. D.; Feil, I. K.; Froning, K. J.; Gao, X.; Hendle, J.; Keegan, K.; Leon, B. C.; Müller-Dieckmann, H. J.; Nienaber, V. L.; Noland, B. W.; Post, K.; Rajashankar, K. R.; Ramos, A.; Russell, M.; Burley, S. K.; Buchanan, S. G. Novel mode of Gleevec binding is revealed by the structure of Spleen Tyrosine Kinase. J. Biol. Chem. 2004, 279, 55827-55832.
36. Sanner, M. F.; Olson, A. J.; Spehner, J. C. Reduced surface: An efficient way to compute molecular surfaces. Biopolymers 1996, 38, 305-320.
37. Knölker, H. J.; Reddy, K. R. Isolation and synthesis of biologically active carbazole alkaloids. Chem. Rev. 2002, 102, 4303-4427.
38. Demetri, G. D.; von Mehren, M.; Blanke, C. D.; Van den Abbeele, A. D.; Eisenberg, B.; Roberts, P. J.; Heinrich, M. C.; Tuveson, D. A.; Singer, S.; Janicek, M.; Fletcher, J. A.; Silverman, S. G.; Silberman, S. L.; Capdeville, R.; Kiese, B.; Peng, B.; Dimitrijevic, S.; Druker, B. J.; Corless, C.; Fletcher, C. D. M.; Joensuu, H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med 2002, 347, 472-480.
39. Halder, J. B.; Lin, Y. G.; Merritt, W. M.; Spannuth, W. A.; Nick, A. M.; Honda, T.; Kamat, A. A.; Han, L.; Kim, T. J.; Lu, C.; Tari, A. M.; Bornmann, W.; Fernández, A.; López-Berestein, G.; Sood, A. K. Therapeutic efficacy of a novel FAK inhibitor TAE226 in ovarian carcinoma. Cancer Res. 2007, 67, 10976-10983.
40. Hauck, C. R.; Hsia, D. A.; Puente, X. S.; Cheresh, D. A.; Schlaepfer, D. D. FRNK blocks v-Src stimulated invasion and experimental metastasis without effects on cell motility or growth. EMBO J. 2002, 21, 6289-6302.
41. Torrance, C. J.; Jackson, P. E.; Montgomery, E.; Kinzler, K. W.; Vogelstein, B.; Wissner, A.; Nunes, M.; Frost, P.; Discafani, C. M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 2000, 6, 1024-1028.
42. Erlichman, C.; Hidalgo, M.; Boni, J. P.; Martins, P.; Quinn, S. E.; Zacharchuk, C.; Amorusi, P.; Adjei, A. A.; Rowinsky, E. K. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. 2006, 24, 2252-2260.
43. Holm, L.; Park, J. DaliLite workbench for protein structure comparison. Bioinformatics 2000, 16, 566-567.
44. DaliLite Pairwise Comparison of Protein Structures, http://www.ebi.ac.uk/ DaliLite/ (accessed May 2008).
45. Agresti, A. Logistic Regression. An Introduction to Categorical Data Analysis. Wiley Interscience: New York, 1996; pp 103-144.
46. Logistic Regression. http://statpages.org/logistic.html (accessed May 2008).
47. Protein Library. http://protlib.uchicago.edu/dloads.html (accessed May 2008).